Adjei Michael D, Heinze Thomas M, Deck Joanna, Freeman James P, Williams Anna J, Sutherland John B
National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA.
Can J Microbiol. 2007 Jan;53(1):144-7. doi: 10.1139/w06-101.
To determine the ability of environmental bacteria to metabolize the frequently prescribed fluoroquinolone drug ciprofloxacin, eight Mycobacterium spp. cultures were grown for 4 days in a medium containing sorbitol and yeast extract with 100 mg x L(-1) ciprofloxacin. After the cultures had been centrifuged and the supernatants extracted with ethyl acetate, two metabolites were purified by using high-performance liquid chromatography. They were identified with liquid chromatography/electrospray ionization mass spectrometry and proton nuclear magnetic resonance spectroscopy. Ciprofloxacin was transformed to both N-acetylciprofloxacin (2.5%-5.5% of the total peak area at 280 nm) and N-nitrosociprofloxacin (6.0%-8.0% of the peak area) by Mycobacterium gilvum PYR-GCK and Mycobacterium sp. PYR100 but it was transformed only to N-acetylciprofloxacin by Mycobacterium frederiksbergense FAn9, M. gilvum ATCC 43909, M. gilvum BB1, Mycobacterium smegmatis mc2155, Mycobacterium sp. 7E1B1W, and Mycobacterium sp. RJGII-135. The results suggest that biotransformation may serve as a ciprofloxacin resistance mechanism for these bacteria.
为了确定环境细菌代谢常用的氟喹诺酮类药物环丙沙星的能力,将8种分枝杆菌属培养物在含有山梨醇、酵母提取物和100 mg x L(-1)环丙沙星的培养基中培养4天。培养物离心后,用乙酸乙酯萃取上清液,通过高效液相色谱法纯化两种代谢产物。用液相色谱/电喷雾电离质谱法和质子核磁共振光谱法对它们进行鉴定。吉尔夫分枝杆菌PYR-GCK和分枝杆菌属PYR100将环丙沙星转化为N-乙酰环丙沙星(在280 nm处占总峰面积的2.5%-5.5%)和N-亚硝基环丙沙星(占峰面积的6.0%-8.0%),但费氏分枝杆菌FAn9、吉尔夫分枝杆菌ATCC 43909、吉尔夫分枝杆菌BB1、耻垢分枝杆菌mc2155、分枝杆菌属7E1B1W和分枝杆菌属RJGII-135仅将其转化为N-乙酰环丙沙星。结果表明,生物转化可能是这些细菌对环丙沙星产生耐药性的一种机制。